Tumor necrosis factor in infectious disease.
Cambridge, United Kingdom. In J Pathol, 04 Apr 2013
TNF signals through two distinct receptors, designated TNFR1 and TNFR2,which initiate diverse cellular effects that include cell survival, activation, differentiation, and proliferation, and cell death.
Two coordinated mechanisms underlie TNFα-induced immediate and delayed IKK activation.
In Mol Cell Biol, 04 Apr 2013
Here, we report by assessing the kinetics and amplitude of IKK activation that TNFα-induced immediate and robust activation of IKK requires K63- and linearly-linked ubiquitination of RIP1, and that in the absence of RIP1 expression TRAF2 and cIAP1 co-operatively induce delayed IKK activation by recruiting LUBAC to TNFR1.
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.
Oxford, United Kingdom. In Nature, Sep 2012
Here we have investigated a single nucleotide polymorphism (SNP) in the TNFRSF1A gene, that encodes tumour necrosis factor receptor 1 (TNFR1), which was discovered through GWAS to be associated with multiple sclerosis (MS), but not with other autoimmune conditions such as rheumatoid arthritis, psoriasis and Crohn’s disease.
The 'complexities' of life and death: death receptor signalling platforms.
Leicester, United Kingdom. In Exp Cell Res, Aug 2012
The role of several of these key multi-protein signalling platforms, namely the DISC, TNFR1 complex I/II, the Necrosome and Ripoptosome, in mediating these pathways will be discussed, as well as the open questions and potential therapeutic benefits of understanding their underlying mechanisms.
Sam68 interacts with IRS1.
Sevilla, Spain. In Biochem Pharmacol, 2012
Sam68 interacts with insulin receptor substrate (IRS)-1 in basal conditions, and insulin increases the affinity between these two partners.
Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases.
Gent, Belgium. In Am J Nephrol, 2011
Binding of TNF-α to the 55-kDa type I TNFR (TNFR1, TNFRSF1A, CD120a, p55) or the 75-kDa type II TNFR (TNFR2, TNFRSF1B, CD120b, p75) activates signaling pathways controlling inflammatory, immune and stress responses, as well as host defense and apoptosis.
Biologic therapies: lessons from multiple sclerosis.
More papers using
Calgary, Canada. In Dig Dis, 2011
TNF receptor 1 (TNFR1) mediates demyelination and TNFR2 mediates remyelination, suggesting that a more selective approach to TNF antagonism may be required for an anti-TNF strategy to be effective in MS.
Lipopolysaccharide-induced increase in signalling in hippocampus is abrogated by IL-10–a role for IL-1 beta?
In Journal of Neuroinflammation, 2003
... anti-phospho-JAK1, anti-phospho-STAT1, STAT1, anti-phospho-IκBα and anti-SOCS3 (Cell Signalling, Danvers, MA, USA), anti-phospho-c-jun and anti-TNFα receptor (TNFR1) (Santa Cruz Biotechnology, Heidelberg, Germany, and anti-actin ...